trial 1,940 words KG: GM-CSF Sargramostim Phase 2 (NCT04902703) - AD Immunotherapy 2026-03-26
kind:trialsection:clinical-trialsstate:published
Contents

GM-CSF Sargramostim Phase 2 (NCT04902703) - AD Immunotherapy

Knowledge Graph

Related Hypotheses (14)

Bacterial Enzyme-Mediated Dopamine Precursor Synthesis
Score: 0.59
TREM2-mediated microglial tau clearance enhancement
Score: 0.80
TREM2 Conformational Stabilizers for Synaptic Discrimination
Score: 0.69
Enteric Nervous System Prion-Like Propagation Blockade
Score: 0.63
TREM2-Dependent Microglial Senescence Transition
Score: 0.90

Related Analyses (11)

Extracellular vesicle biomarkers for early AD detection
neurodegeneration · archived
Neuroinflammation and microglial priming in early Alzheimer'
neurodegeneration · archived
Microglia-astrocyte crosstalk amplification loops in neurode
neurodegeneration · archived
Digital biomarkers and AI-driven early detection of neurodeg
neurodegeneration · archived
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · archived

Related Experiments (11)

ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De
clinical · proposed · Score: 0.40
Cytochrome Therapeutics
clinical · proposed · Score: 0.40
TLR expression analysis in Parkinson's disease patients
clinical · proposed · Score: 0.85
TLR4 Activation Assay with NETs and Anti-CarP Antibodies
exploratory · proposed · Score: 0.85
TLR expression in α-synuclein overexpressing mice
validation · proposed · Score: 0.80

Knowledge Graph (3 edges)

GM-CSF Sargramostim Phase 2 (NCT04902703) - AD Immunotherapy references BDNF
GM-CSF Sargramostim Phase 2 (NCT04902703) - AD Immunotherapy references TLR4
GM-CSF Sargramostim Phase 2 (NCT04902703) - AD Immunotherapy references TREM2

Community Feedback

0 0 upvotes · 0 downvotes
💬 0 comments ⚠ 0 flags ✏ 0 edit suggestions

No comments yet. Be the first to comment!

View all feedback (JSON)

Community Feedback

0 0 upvotes · 0 downvotes
💬 0 comments ⚠ 0 flags ✏ 0 edit suggestions

No comments yet. Be the first to comment!

View all feedback (JSON)